Biomarker analysis of the study showed that this shrinking process was much reduced, he said
Both formulations contain the same active ingredient but differ in dosing protocols and FDA-approved indications
Plaintiffs contend that manufacturers knew or should have known about the association between GLP-1 receptor agonists and non-arteritic anterior ischemic optic neuropathy (NAION), yet omitted this critical information from drug labels and prescribing materials
Julie Paik, associate professor of medicine in the Division of Pharmacoepidemiology and Pharmacoeconomics and the Division of Renal (Kidney) Medicine at Brigham and Womens Hospital in Boston, MA, and corresponding author of this study, said her research group decided to examine SGLT2 inhibitors as a possible way to lower kidney stone risk because they had already been studying this newer class of diabetes medications for several years
Three key insights emerge from this comprehensive analysis
It can be surprising, and for many, frustrating to feel healthier than ever while noticing an aging shift in their face